Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression.

Thiem A, Hesbacher S, Kneitz H, di Primio T, Heppt MV, Hermanns HM, Goebeler M, Meierjohann S, Houben R, Schrama D.

J Exp Clin Cancer Res. 2019 Sep 11;38(1):397. doi: 10.1186/s13046-019-1403-9.

2.

Role of melanoma inhibitory activity in melanocyte senescence.

Feuerer L, Lamm S, Henz I, Kappelmann-Fenzl M, Haferkamp S, Meierjohann S, Hellerbrand C, Kuphal S, Bosserhoff AK.

Pigment Cell Melanoma Res. 2019 Nov;32(6):777-791. doi: 10.1111/pcmr.12801. Epub 2019 Jun 21.

PMID:
31172672
3.

The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.

Appenzeller S, Gesierich A, Thiem A, Hufnagel A, Jessen C, Kneitz H, Regensburger M, Schmidt C, Zirkenbach V, Bischler T, Schilling B, Siedel C, Goebeler ME, Houben R, Schrama D, Gehrig A, Rost S, Maurus K, Bargou R, Rosenwald A, Schartl M, Goebeler M, Meierjohann S.

Cancer. 2019 Feb 15;125(4):586-600. doi: 10.1002/cncr.31843. Epub 2018 Dec 18.

PMID:
30561760
4.

BRAF inhibition causes resilience of melanoma cell lines by inducing the secretion of FGF1.

Grimm J, Hufnagel A, Wobser M, Borst A, Haferkamp S, Houben R, Meierjohann S.

Oncogenesis. 2018 Sep 20;7(9):71. doi: 10.1038/s41389-018-0082-2.

5.

RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas.

Kunz M, Löffler-Wirth H, Dannemann M, Willscher E, Doose G, Kelso J, Kottek T, Nickel B, Hopp L, Landsberg J, Hoffmann S, Tüting T, Zigrino P, Mauch C, Utikal J, Ziemer M, Schulze HJ, Hölzel M, Roesch A, Kneitz S, Meierjohann S, Bosserhoff A, Binder H, Schartl M.

Oncogene. 2018 Nov;37(47):6136-6151. doi: 10.1038/s41388-018-0385-y. Epub 2018 Jul 11.

PMID:
29995873
6.

Early onset of diffuse melanosis cutis under pembrolizumab therapy illustrates the limitations of anti-PD-1 checkpoint inhibitors.

Thiem A, Schummer P, Ueberschaar S, Kerstan A, Kneitz H, Schrama D, Appenzeller S, Meierjohann S, Schilling B, Goebeler M, Gesierich A.

Melanoma Res. 2018 Oct;28(5):465-468. doi: 10.1097/CMR.0000000000000458.

PMID:
29781871
7.

Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma.

Yu Y, Schleich K, Yue B, Ji S, Lohneis P, Kemper K, Silvis MR, Qutob N, van Rooijen E, Werner-Klein M, Li L, Dhawan D, Meierjohann S, Reimann M, Elkahloun A, Treitschke S, Dörken B, Speck C, Mallette FA, Zon LI, Holmen SL, Peeper DS, Samuels Y, Schmitt CA, Lee S.

Cancer Cell. 2018 Apr 9;33(4):785. doi: 10.1016/j.ccell.2018.03.009. No abstract available.

8.

Panel Sequencing Shows Recurrent Genetic FAS Alterations in Primary Cutaneous Marginal Zone Lymphoma.

Maurus K, Appenzeller S, Roth S, Kuper J, Rost S, Meierjohann S, Arampatzi P, Goebeler M, Rosenwald A, Geissinger E, Wobser M.

J Invest Dermatol. 2018 Jul;138(7):1573-1581. doi: 10.1016/j.jid.2018.02.015. Epub 2018 Feb 23.

9.

Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma.

Yu Y, Schleich K, Yue B, Ji S, Lohneis P, Kemper K, Silvis MR, Qutob N, van Rooijen E, Werner-Klein M, Li L, Dhawan D, Meierjohann S, Reimann M, Elkahloun A, Treitschke S, Dörken B, Speck C, Mallette FA, Zon LI, Holmen SL, Peeper DS, Samuels Y, Schmitt CA, Lee S.

Cancer Cell. 2018 Feb 12;33(2):322-336.e8. doi: 10.1016/j.ccell.2018.01.002. Erratum in: Cancer Cell. 2018 Apr 9;33(4):785.

10.

BIK is involved in BRAF/MEK inhibitor induced apoptosis in melanoma cell lines.

Borst A, Haferkamp S, Grimm J, Rösch M, Zhu G, Guo S, Li C, Gao T, Meierjohann S, Schrama D, Houben R.

Cancer Lett. 2017 Sep 28;404:70-78. doi: 10.1016/j.canlet.2017.07.005. Epub 2017 Jul 15.

PMID:
28720543
11.

The AP-1 transcription factor FOSL1 causes melanocyte reprogramming and transformation.

Maurus K, Hufnagel A, Geiger F, Graf S, Berking C, Heinemann A, Paschen A, Kneitz S, Stigloher C, Geissinger E, Otto C, Bosserhoff A, Schartl M, Meierjohann S.

Oncogene. 2017 Sep 7;36(36):5110-5121. doi: 10.1038/onc.2017.135. Epub 2017 May 8.

PMID:
28481878
12.

Crosstalk signaling in targeted melanoma therapy.

Meierjohann S.

Cancer Metastasis Rev. 2017 Mar;36(1):23-33. doi: 10.1007/s10555-017-9659-z. Review.

PMID:
28197745
13.

Peroxiredoxin 6 triggers melanoma cell growth by increasing arachidonic acid-dependent lipid signalling.

Schmitt A, Schmitz W, Hufnagel A, Schartl M, Meierjohann S.

Biochem J. 2015 Oct 15;471(2):267-79. doi: 10.1042/BJ20141204. Epub 2015 Aug 18.

PMID:
26285655
14.

Hypoxia-independent drivers of melanoma angiogenesis.

Meierjohann S.

Front Oncol. 2015 May 5;5:102. doi: 10.3389/fonc.2015.00102. eCollection 2015. Review.

15.

In vitro evidence for senescent multinucleated melanocytes as a source for tumor-initiating cells.

Leikam C, Hufnagel AL, Otto C, Murphy DJ, Mühling B, Kneitz S, Nanda I, Schmid M, Wagner TU, Haferkamp S, Bröcker EB, Schartl M, Meierjohann S.

Cell Death Dis. 2015 Apr 2;6:e1711. doi: 10.1038/cddis.2015.71.

16.

The MAPK pathway as an apoptosis enhancer in melanoma.

Haydn JM, Hufnagel A, Grimm J, Maurus K, Schartl M, Meierjohann S.

Oncotarget. 2014 Jul 15;5(13):5040-53.

17.

Oxidative stress in melanocyte senescence and melanoma transformation.

Meierjohann S.

Eur J Cell Biol. 2014 Jan-Feb;93(1-2):36-41. doi: 10.1016/j.ejcb.2013.11.005. Epub 2013 Nov 23. Review.

PMID:
24342719
18.

Tumor angiogenesis is caused by single melanoma cells in a manner dependent on reactive oxygen species and NF-κB.

Schaafhausen MK, Yang WJ, Centanin L, Wittbrodt J, Bosserhoff A, Fischer A, Schartl M, Meierjohann S.

J Cell Sci. 2013 Sep 1;126(Pt 17):3862-72. doi: 10.1242/jcs.125021. Epub 2013 Jul 10.

19.

Cystathionase mediates senescence evasion in melanocytes and melanoma cells.

Leikam C, Hufnagel A, Walz S, Kneitz S, Fekete A, Müller MJ, Eilers M, Schartl M, Meierjohann S.

Oncogene. 2014 Feb 6;33(6):771-82. doi: 10.1038/onc.2012.641. Epub 2013 Jan 28.

PMID:
23353821
20.

Vemurafenib induces senescence features in melanoma cells.

Haferkamp S, Borst A, Adam C, Becker TM, Motschenbacher S, Windhövel S, Hufnagel AL, Houben R, Meierjohann S.

J Invest Dermatol. 2013 Jun;133(6):1601-9. doi: 10.1038/jid.2013.6. Epub 2013 Feb 14.

21.

Hyperactivation of constitutively dimerized oncogenic EGF receptors by autocrine loops.

Laisney JA, Mueller TD, Schartl M, Meierjohann S.

Oncogene. 2013 May 9;32(19):2403-11. doi: 10.1038/onc.2012.267. Epub 2012 Jul 2.

PMID:
22751127
22.

Conserved expression signatures between medaka and human pigment cell tumors.

Schartl M, Kneitz S, Wilde B, Wagner T, Henkel CV, Spaink HP, Meierjohann S.

PLoS One. 2012;7(5):e37880. doi: 10.1371/journal.pone.0037880. Epub 2012 May 31.

23.

Inducible and repressable oncogene-addicted hepatocellular carcinoma in Tet-on xmrk transgenic zebrafish.

Li Z, Huang X, Zhan H, Zeng Z, Li C, Spitsbergen JM, Meierjohann S, Schartl M, Gong Z.

J Hepatol. 2012 Feb;56(2):419-25. doi: 10.1016/j.jhep.2011.07.025. Epub 2011 Aug 31.

PMID:
21888874
24.

ETS-1/RhoC signaling regulates the transcription factor c-Jun in melanoma.

Spangler B, Kappelmann M, Schittek B, Meierjohann S, Vardimon L, Bosserhoff AK, Kuphal S.

Int J Cancer. 2012 Jun 15;130(12):2801-11. doi: 10.1002/ijc.26277. Epub 2011 Aug 12.

25.

MMP13 mediates cell cycle progression in melanocytes and melanoma cells: in vitro studies of migration and proliferation.

Meierjohann S, Hufnagel A, Wende E, Kleinschmidt MA, Wolf K, Friedl P, Gaubatz S, Schartl M.

Mol Cancer. 2010 Jul 28;9:201. doi: 10.1186/1476-4598-9-201.

26.

Gene expression analysis after receptor tyrosine kinase activation reveals new potential melanoma proteins.

Teutschbein J, Haydn JM, Samans B, Krause M, Eilers M, Schartl M, Meierjohann S.

BMC Cancer. 2010 Jul 21;10:386. doi: 10.1186/1471-2407-10-386.

27.

Multicentre study on standardisation of melanoma cell culture--an initiative of the German Melanoma Research Network.

Eberle J, Spangler B, Becker JC, Heinemann SH, Klein CA, Kunz M, Kuphal S, Langer P, Mauch C, Meierjohann S, Paschen A, Schadendorf D, Schartl M, Schittek B, Schönherr R, Tüting T, Zigrino P, Bosserhoff AK; German Melanoma Research Network of the German Cancer Aid.

Pigment Cell Melanoma Res. 2010 Apr;23(2):296-8. doi: 10.1111/j.1755-148X.2010.00684.x. Epub 2010 Feb 5. No abstract available.

PMID:
20137059
28.

Lineage-specific co-evolution of the Egf receptor/ligand signaling system.

Laisney JA, Braasch I, Walter RB, Meierjohann S, Schartl M.

BMC Evol Biol. 2010 Jan 27;10:27. doi: 10.1186/1471-2148-10-27.

29.

A mutated EGFR is sufficient to induce malignant melanoma with genetic background-dependent histopathologies.

Schartl M, Wilde B, Laisney JA, Taniguchi Y, Takeda S, Meierjohann S.

J Invest Dermatol. 2010 Jan;130(1):249-58. doi: 10.1038/jid.2009.213.

30.

Quantitative differential proteome analysis in an animal model for human melanoma.

Lokaj K, Meierjohann S, Schütz C, Teutschbein J, Schartl M, Sickmann A.

J Proteome Res. 2009 Apr;8(4):1818-27. doi: 10.1021/pr800578a.

PMID:
19249851
31.

Interaction of Xiphophorus and murine Fyn with focal adhesion kinase.

Teutschbein J, Schartl M, Meierjohann S.

Comp Biochem Physiol C Toxicol Pharmacol. 2009 Mar;149(2):168-74. doi: 10.1016/j.cbpc.2008.09.013. Epub 2008 Sep 30.

PMID:
18930841
32.

Oncogene activation in melanocytes links reactive oxygen to multinucleated phenotype and senescence.

Leikam C, Hufnagel A, Schartl M, Meierjohann S.

Oncogene. 2008 Nov 27;27(56):7070-82. doi: 10.1038/onc.2008.323. Epub 2008 Sep 22.

PMID:
18806824
33.

A structural model of the extracellular domain of the oncogenic EGFR variant Xmrk.

Meierjohann S, Mueller T, Schartl M, Buehner M.

Zebrafish. 2006;3(3):359-69. doi: 10.1089/zeb.2006.3.359.

PMID:
18377216
34.

STAT3 and BMP-receptor 1a functionally interact in different stem cell types.

Wagner T, Meierjohann S, Reiss C, Federov L, Kraeussling M, Thoma E, Kneitz B, Schartl M.

J Stem Cells Regen Med. 2007 May 16;2(1):172. eCollection 2007. No abstract available.

PMID:
24692980
35.

From Mendelian to molecular genetics: the Xiphophorus melanoma model.

Meierjohann S, Schartl M.

Trends Genet. 2006 Dec;22(12):654-61. Epub 2006 Oct 10. Review.

PMID:
17034900
36.
37.

Genetic, biochemical and evolutionary facets of Xmrk-induced melanoma formation in the fish Xiphophorus.

Meierjohann S, Schartl M, Volff JN.

Comp Biochem Physiol C Toxicol Pharmacol. 2004 Jul;138(3):281-9. Review.

PMID:
15533786
39.

Glutathione synthetase from Plasmodium falciparum.

Meierjohann S, Walter RD, Müller S.

Biochem J. 2002 May 1;363(Pt 3):833-8.

40.

Thioredoxin and glutathione system of malaria parasite Plasmodium falciparum.

Müller S, Gilberger TW, Krnajski Z, Lüersen K, Meierjohann S, Walter RD.

Protoplasma. 2001;217(1-3):43-9. Review.

PMID:
11732337

Supplemental Content

Loading ...
Support Center